6533b823fe1ef96bd127e08a

RESEARCH PRODUCT

A randomized, multicenter, open-label controlled phase 2 trial of Foxy-5 as neoadjuvant therapy in patients with WNT5A negative colon cancer

R. SalazarJ. GullboK. JohanssonJ. VermorkenAndrés CervantesP. MorsingN. Lindland RoestT. Andersson

subject

Oncologymedicine.medical_specialtybusiness.industryColorectal cancermedicine.medical_treatmentHematologymedicine.diseaseWNT5AOncologyInternal medicineMedicineIn patientOpen labelbusinessNeoadjuvant therapyWnt 5a proteinhttps://doi.org/10.1093/annonc/mdz155.132